title: Are respiratory complications more likely in patients with pulmonary aspergillosis treated with echinocandins in the setting of neutrophil influx?
authors.affiliation: Department of Infectious Diseases, Infection Control and Employee Health; The University of Texas M.D. Anderson Cancer Center; Houston, TX USA.
authors.forename: Dimitrios P
authors.initials: DP
authors.lastname: Kontoyiannis
mesh_terms: D019264:Adoptive Transfer / Q000009:adverse effects*; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D054714:Echinocandins / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000453:epidemiology*; D009504:Neutrophils / Q000276:immunology*; D055732:Pulmonary Aspergillosis / Q000150:complications* / Q000276:immunology / Q000628:therapy*
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins
keywords: IRIS; echinocandins; granulocyte transfusions; neutrophils; pulmonary aspergillosis; respiratory complications